Novavax to Participate in Upcoming Conferences
|J.P. Morgan 39th Annual Healthcare Conference|
|Webcast:||www.novavax.com, “Investors” / “Events”|
|13th Annual Biotech Showcase|
|Panel title:||In Conversation with COVID-19 Leaders: The Novavax COVID-19 Journey|
|Webcast:||A replay of the recorded fireside session will be available through the events page of the Company’s website at ir.novavax.com for 90 days.|
NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. NVX-CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike (S) protein. It is adjuvanted with Novavax’ patented saponin-based Matrix-M™ to enhance the immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19. In preclinical studies, NVX-CoV2373 induced antibodies that block binding of spike protein to cellular receptors and provided protection from infection and disease. NVX-CoV2373 was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera in Phase 1/2 clinical testing. NVX-CoV2373 is currently being evaluated in two pivotal Phase 3 trials: a trial in the
Novavax’ patented saponin-based Matrix-M™ adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response.
Novavax Forward Looking Statements
Statements herein relating to the future of
Source: Novavax, Inc.